LON:MTFB - Motif Bio Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 32 -0.10 (-0.31 %)
(As of 05/24/2018 04:00 PM ET)
Previous CloseGBX 32
Today's RangeGBX 31.28 - GBX 32.05
52-Week RangeGBX 23.50 - GBX 51.75
Volume412,949 shs
Average Volume400,302 shs
Market Capitalization£93.75 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Motif Bio (LON:MTFB)

Motif Bio logoMotif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Receive MTFB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTFB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:MTFB
CUSIPN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-773.10%
Return on Assets-183.64%

Miscellaneous

EmployeesN/A
Outstanding Shares263,130,000

Motif Bio (LON:MTFB) Frequently Asked Questions

What is Motif Bio's stock symbol?

Motif Bio trades on the London Stock Exchange (LON) under the ticker symbol "MTFB."

What price target have analysts set for MTFB?

5 equities research analysts have issued 1 year price targets for Motif Bio's stock. Their forecasts range from GBX 100 to GBX 115. On average, they anticipate Motif Bio's share price to reach GBX 109.20 in the next year. View Analyst Ratings for Motif Bio.

Who are some of Motif Bio's key competitors?

Who are Motif Bio's key executives?

Motif Bio's management team includes the folowing people:
  • Mr. Graham George Lumsden, CEO & Exec. Director (Age 58)
  • Mr. Jonathan E. Gold, Interim CFO, Strategic Financial Consultant & Non-Exec. Director (Age 45)
  • Mr. Robert Joseph Bertoldi, Exec. Director (Age 64)
  • Dr. David B. Huang M.D., Ph.D., MBA, J.D., Chief Medical Officer (Age 43)
  • Mr. Robert Dickey IV, Advisor (Age 62)

Has Motif Bio been receiving favorable news coverage?

Media headlines about MTFB stock have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Motif Bio earned a news impact score of 0.02 on Accern's scale. They also gave news coverage about the company an impact score of 46.83 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Motif Bio?

Shares of MTFB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Motif Bio's stock price today?

One share of MTFB stock can currently be purchased for approximately GBX 32.

How big of a company is Motif Bio?

Motif Bio has a market capitalization of £93.75 million.


MarketBeat Community Rating for Motif Bio (MTFB)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  254 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  419
MarketBeat's community ratings are surveys of what our community members think about Motif Bio and other stocks. Vote "Outperform" if you believe MTFB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTFB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Motif Bio (LON:MTFB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Motif Bio in the last 12 months. Their average twelve-month price target is GBX 109.20The high price target for MTFB is GBX 115 and the low price target for MTFB is GBX 100. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.752.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 109.20GBX 101.50GBX 102GBX 101.50

Motif Bio (LON:MTFB) Consensus Price Target History

Price Target History for Motif Bio (LON:MTFB)

Motif Bio (LON:MTFB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/18/2018Northland SecuritiesReiterated RatingBuyView Rating Details
5/4/2018Northland Capital PartnersReiterated RatingBuyGBX 115View Rating Details
5/1/2018Peel HuntReiterated RatingBuyView Rating Details
11/22/2017FinnCapReiterated RatingBuyGBX 100View Rating Details
11/16/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 110View Rating Details
1/9/2017Rodman & RenshawInitiated CoverageBuyView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Dividends

Motif Bio (LON:MTFB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Motif Bio (LON MTFB) Insider Trading and Institutional Ownership History

Insider Trading History for Motif Bio (LON:MTFB)

Motif Bio (LON MTFB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/5/2015Stakes III,John WilburInsiderBuy100,000GBX 60£60,000
(Data available from 1/1/2013 forward)

Headlines

Motif Bio (LON MTFB) News Headlines

Source:
DateHeadline
Motif (MTFB) Given Buy Rating at Northland SecuritiesMotif (MTFB) Given Buy Rating at Northland Securities
www.americanbankingnews.com - May 18 at 10:16 AM
Northland Securities Reaffirms "Buy" Rating for Motif (MTFB)Northland Securities Reaffirms "Buy" Rating for Motif (MTFB)
www.americanbankingnews.com - May 8 at 10:38 AM
Motif (MTFB) Given Buy Rating at Northland Capital PartnersMotif (MTFB) Given Buy Rating at Northland Capital Partners
www.americanbankingnews.com - May 5 at 2:45 AM
Motifs (MTFB) Buy Rating Reaffirmed at Peel HuntMotif's (MTFB) Buy Rating Reaffirmed at Peel Hunt
www.americanbankingnews.com - May 1 at 6:46 AM
FinnCap Reiterates Buy Rating for Motif (MTFB)FinnCap Reiterates Buy Rating for Motif (MTFB)
www.americanbankingnews.com - April 12 at 3:26 PM
Motifs (MTFB) "Buy" Rating Reaffirmed at Northland SecuritiesMotif's (MTFB) "Buy" Rating Reaffirmed at Northland Securities
www.americanbankingnews.com - April 12 at 11:59 AM
One ‘secret’ growth stock I’d buy alongside this FTSE 100 growth monsterOne ‘secret’ growth stock I’d buy alongside this FTSE 100 growth monster
www.fool.co.uk - April 10 at 4:05 PM
Motif (MTFB) Stock Rating Reaffirmed by Peel HuntMotif (MTFB) Stock Rating Reaffirmed by Peel Hunt
www.americanbankingnews.com - April 10 at 8:41 AM
Motif (MTFB) Earns "Buy" Rating from Northland SecuritiesMotif (MTFB) Earns "Buy" Rating from Northland Securities
www.americanbankingnews.com - April 10 at 8:26 AM
Motif (MTFB) Receives "Speculative Buy" Rating from Beaufort SecuritiesMotif (MTFB) Receives "Speculative Buy" Rating from Beaufort Securities
www.americanbankingnews.com - April 8 at 3:42 PM
Motif (MTFB) Earns Buy Rating from FinnCapMotif (MTFB) Earns Buy Rating from FinnCap
www.americanbankingnews.com - April 8 at 12:06 AM
Motif (MTFB) Given "Buy" Rating at Peel HuntMotif (MTFB) Given "Buy" Rating at Peel Hunt
www.americanbankingnews.com - April 3 at 10:30 PM
Motif (MTFB) Receives "Buy" Rating from Northland Capital PartnersMotif (MTFB) Receives "Buy" Rating from Northland Capital Partners
www.americanbankingnews.com - April 3 at 10:40 AM
Peel Hunt Reiterates Buy Rating for Motif (MTFB)Peel Hunt Reiterates Buy Rating for Motif (MTFB)
www.americanbankingnews.com - April 3 at 10:16 AM
Motif (MTFB) Rating Reiterated by Northland SecuritiesMotif (MTFB) Rating Reiterated by Northland Securities
www.americanbankingnews.com - April 3 at 10:16 AM
Motifs (MTFB) "Buy" Rating Reiterated at Peel HuntMotif's (MTFB) "Buy" Rating Reiterated at Peel Hunt
www.americanbankingnews.com - March 29 at 7:28 PM
Motif Bios (MTFB) "Buy" Rating Reiterated at Peel HuntMotif Bio's (MTFB) "Buy" Rating Reiterated at Peel Hunt
www.americanbankingnews.com - March 26 at 12:04 AM
Motif Bio (MTFB) Price Target Cut to GBX 106 by Analysts at Peel HuntMotif Bio (MTFB) Price Target Cut to GBX 106 by Analysts at Peel Hunt
www.americanbankingnews.com - March 24 at 12:54 PM
Motif Bio (MTFB) Receives "Buy" Rating from Northland Capital PartnersMotif Bio (MTFB) Receives "Buy" Rating from Northland Capital Partners
www.americanbankingnews.com - March 20 at 4:42 PM
Northland Securities Reaffirms "Buy" Rating for Motif Bio (MTFB)Northland Securities Reaffirms "Buy" Rating for Motif Bio (MTFB)
www.americanbankingnews.com - March 19 at 10:52 AM
Motif Bio Issues 178,571 Shares Following Warrants Exercise (ALLISS)Motif Bio Issues 178,571 Shares Following Warrants Exercise (ALLISS)
www.morningstar.co.uk - March 8 at 10:25 AM
Motif Bio to Present Iclaprim Data at ECCMID 2018 - GlobeNewswire (press release)Motif Bio to Present Iclaprim Data at ECCMID 2018 - GlobeNewswire (press release)
globenewswire.com - February 23 at 4:29 PM
Motif Bio (MTFB) Stock Rating Reaffirmed by Northland SecuritiesMotif Bio (MTFB) Stock Rating Reaffirmed by Northland Securities
www.americanbankingnews.com - February 5 at 7:22 AM
Appointment of Jonathan E. Gold as Interim Chief Financial Officer - GlobeNewswire (press release)Appointment of Jonathan E. Gold as Interim Chief Financial Officer - GlobeNewswire (press release)
globenewswire.com - February 4 at 8:48 AM
Motif Bio Announces Filing of US Shelf Registration - GlobeNewswire (press release)Motif Bio Announces Filing of US Shelf Registration - GlobeNewswire (press release)
globenewswire.com - January 19 at 5:23 PM
Motif Bio (MTFB) Rating Reiterated by Northland SecuritiesMotif Bio (MTFB) Rating Reiterated by Northland Securities
www.americanbankingnews.com - January 16 at 6:40 AM
Motif Bio (MTFB) Earns Buy Rating from Peel HuntMotif Bio (MTFB) Earns Buy Rating from Peel Hunt
www.americanbankingnews.com - December 22 at 10:40 PM
Motif Bios (MTFB) "Buy" Rating Reaffirmed at Northland SecuritiesMotif Bio's (MTFB) "Buy" Rating Reaffirmed at Northland Securities
www.americanbankingnews.com - December 22 at 1:02 PM
Motif Bio REVIVE-1 Phase 3 Study Results with Iclaprim Published ... - GlobeNewswire (press release)Motif Bio REVIVE-1 Phase 3 Study Results with Iclaprim Published ... - GlobeNewswire (press release)
globenewswire.com - December 21 at 4:57 PM
Poor Industry Group Rank Drops Motif Bio (MTFB) to Hold - Investorplace.comPoor Industry Group Rank Drops Motif Bio (MTFB) to Hold - Investorplace.com
investorplace.com - December 2 at 4:47 PM
Poor Industry Group Rank Drops Motif Bio (MTFB) to HoldPoor Industry Group Rank Drops Motif Bio (MTFB) to Hold
investorplace.com - December 1 at 10:56 AM
Motif Bio (MTFB) Sees Rating Drop….. Wilting Earnings Growth - Investorplace.comMotif Bio (MTFB) Sees Rating Drop….. Wilting Earnings Growth - Investorplace.com
investorplace.com - November 25 at 9:32 AM
Motif Bio plc (MTFB) Given "Buy" Rating at FinnCapMotif Bio plc (MTFB) Given "Buy" Rating at FinnCap
www.americanbankingnews.com - November 23 at 10:01 PM
Motif Bio plc (MTFB) Rating Reiterated by Northland SecuritiesMotif Bio plc (MTFB) Rating Reiterated by Northland Securities
www.americanbankingnews.com - November 19 at 11:36 PM
Peel Hunt Reaffirms "Buy" Rating for Motif Bio plc (MTFB)Peel Hunt Reaffirms "Buy" Rating for Motif Bio plc (MTFB)
www.americanbankingnews.com - November 19 at 10:58 PM
Motif Bio plc (MTFB) Receives Speculative Buy Rating from Beaufort SecuritiesMotif Bio plc (MTFB) Receives Speculative Buy Rating from Beaufort Securities
www.americanbankingnews.com - November 19 at 6:16 AM
Motif Bio PLC (MTFB) Receives "Buy" Rating from FinnCapMotif Bio PLC (MTFB) Receives "Buy" Rating from FinnCap
www.americanbankingnews.com - November 18 at 10:52 PM
Motif Bio secures up to US$20 million debt financing - GlobeNewswire (press release)Motif Bio secures up to US$20 million debt financing - GlobeNewswire (press release)
globenewswire.com - November 15 at 6:33 AM
Motif Bio PLC (MTFB) Stock Rating Reaffirmed by Northland SecuritiesMotif Bio PLC (MTFB) Stock Rating Reaffirmed by Northland Securities
www.americanbankingnews.com - October 8 at 1:34 PM
Motif Bio PLC (MTFB) Coverage Initiated by Analysts at Peel HuntMotif Bio PLC (MTFB) Coverage Initiated by Analysts at Peel Hunt
www.americanbankingnews.com - October 8 at 11:16 AM
Motif Bio Presents New Pre-Clinical Data for Iclaprim at IDWeek 2017™ - GlobeNewswire (press release)Motif Bio Presents New Pre-Clinical Data for Iclaprim at IDWeek 2017™ - GlobeNewswire (press release)
globenewswire.com - October 6 at 9:32 AM
Should I pile into Motif Bio plc, up 35% today?Should I pile into Motif Bio plc, up 35% today?
www.fool.co.uk - October 5 at 9:33 AM
Why You Need To Look At This Factor Before Buying Motif Bio plc (MTFB)Why You Need To Look At This Factor Before Buying Motif Bio plc (MTFB)
finance.yahoo.com - October 5 at 9:33 AM
Motif Bio PLC (MTFB) Given Buy Rating at Northland SecuritiesMotif Bio PLC (MTFB) Given Buy Rating at Northland Securities
www.americanbankingnews.com - September 29 at 7:14 AM
Northland Securities Reiterates Buy Rating for Motif Bio PLC (MTFB)Northland Securities Reiterates Buy Rating for Motif Bio PLC (MTFB)
www.americanbankingnews.com - September 18 at 7:06 AM
Motif Bio to Host Investor and Analyst Event on September 20, 2017 in New York - GlobeNewswire (press release)Motif Bio to Host Investor and Analyst Event on September 20, 2017 in New York - GlobeNewswire (press release)
globenewswire.com - September 9 at 6:25 AM
Motif Bio to present at upcoming investor and scientific conferences - GlobeNewswire (press release)Motif Bio to present at upcoming investor and scientific conferences - GlobeNewswire (press release)
globenewswire.com - September 1 at 6:06 AM
FinnCap Reaffirms "Buy" Rating for Motif Bio PLC (MTFB)FinnCap Reaffirms "Buy" Rating for Motif Bio PLC (MTFB)
www.americanbankingnews.com - August 28 at 5:36 PM
Motif Bio PLCs (MTFB) Buy Rating Reaffirmed at Northland SecuritiesMotif Bio PLC's (MTFB) Buy Rating Reaffirmed at Northland Securities
www.americanbankingnews.com - July 9 at 9:24 AM
Motif Bio Announces Result of General Meeting and Total Voting RightsMotif Bio Announces Result of General Meeting and Total Voting Rights
www.nasdaq.com - June 23 at 7:10 PM

SEC Filings

Motif Bio (LON:MTFB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Motif Bio (LON MTFB) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.